Please login to the form below

Not currently logged in
Email:
Password:

Osmotica Pharmaceuticals appoints new vice president

Samer Kaba joins the firm

Osmotica Pharmaceuticals has appointed Samer Kaba as vice president and head of global clinical development and medical affairs.

Kaba brings experience in developing pharmaceutical products for neurology, analgesia, and autoimmune diseases and has spent 15 years in the pharmaceutical industry in global clinical development programmes from early to late stage development and submission of NDAs and global marketing authorisations.

Praveen Tyle, president and CEO of Osmotica, said: “We are very pleased to have Samer as part of our senior leadership team at such an exciting time as he will be instrumental in further progressing Osmotica's recent achievements in our two lead CNS product candidates – Ontinua ER and Osmolex ER.

“Dr. Kaba's experience in multiple sclerosis will also be instrumental in discussions with FDA for the approval of Ontinua ER, which was accepted for filing by the FDA recently.”

8th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics